Evidence map›Paper›PMID 35011949›Full record

ArticleJournal of clinical medicine2021

Virus-Induced Risk of Hepatocellular Carcinoma: Recent Progress and Future Challenges.

Joachim Lupberger, Thomas F Baumert

Abstract readEditorial
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Joachim LupbergerInstitut National de la Santé et de la Recherche Médicale, U1110, 67000 Strasbourg, France.ORCID 0000-0003-3996-3907
Thomas F BaumertInstitut National de la Santé et de la Recherche Médicale, U1110, 67000 Strasbourg, France.ORCID 0000-0002-8864-2168

Funding

Reverse-engineering precision liver cancer chemopreventionR01CA233794 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN · 2019 to 2023
$3.5M
European Research Council 671231European Research Council 862551European Union 667273French agency for the research on viral hepatitis and emerging viruses (ANRS) ECTZ103701French agency for the research on viral hepatitis and emerging viruses (ANRS) ECTZ104017French agency for the research on viral hepatitis and emerging viruses (ANRS) ECTZ131760French agency for the research on viral hepatitis and emerging viruses (ANRS) ECTZ160436French agency for the research on viral hepatitis and emerging viruses (ANRS) ECTZ171594French agency for the research on viral hepatitis and emerging viruses (ANRS) ECTZ75178French Cancer Agency (ARC) IHU201901299Inserm Plan Cancer 2019-2023NIH HHS R01CA233794The Fondation de l'Université de Strasbourg (HEPKIN) TBA-DON-0002
6 · The paper itself

Abstract

Chronic viral hepatitis is a key risk factor for liver fibrosis and hepatocellular carcinoma (HCC) [...].

Identifiers

PMID35011949
PMCPMC8745496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.